Regulatory Framework for Academic Investigator-Sponsored Investigational New Drug Development of Cell and Gene Therapies in the USA.

Autor: Dasgupta A; Expression Manufacturing LLC, West Chester, OH USA., Herzegh K; Marcus Center for Pediatric Cellular Therapies, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University, Atlanta, GA USA., Spencer HT; Cell and Gene Therapy Program, Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University, Atlanta, GA USA., Doering C; Cell and Gene Therapy Program, Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University, Atlanta, GA USA., Day E; Expression Manufacturing LLC, West Chester, OH USA., Swaney WP; Expression Manufacturing LLC, West Chester, OH USA.
Jazyk: angličtina
Zdroj: Current stem cell reports [Curr Stem Cell Rep] 2021; Vol. 7 (4), pp. 129-139. Date of Electronic Publication: 2021 Sep 30.
DOI: 10.1007/s40778-021-00196-4
Abstrakt: Purpose of Review: The promise of cell and gene therapy (CGT) products for a multitude of diseases has revitalized investigators to advance novel CGT product candidates to first-in-human trials by pursuing the investigational new drug (IND) mechanism administered by the United States (US) Food and Drug Administration (FDA). This review is intended to familiarize academic investigators with the IND governing regulations set forth by the FDA.
Recent Findings: CGT products are extraordinarily complex biologics and, therefore, early-stage evaluation programs must be customized to satisfactorily address their unique developmental challenges. The US FDA continues to foster the development of transformational technology that will facilitate the broad application of safe and effective gene therapy products that have the potential to alleviate many conditions previously out of reach of therapeutic intervention. FDA is committed to working with the scientific community and industry to facilitate the availability of these treatments to patients.
Summary: The pathway to meet regulatory compliance during early stage IND programs can be daunting to academic investigators interested in CGT product development that typically don't progress beyond phase 1/2. However, by keeping abreast of current regulatory framework and building upon FDA's supportive infrastructure, an investigator can be well-positioned to advance innovative scientific discoveries towards early stage clinical assessments.
Competing Interests: Conflict of InterestDr. Doering reports other from Expression Therapeutics, Inc., during the conduct of the study. The other authors declare that they have no conflict of interest.
(© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021.)
Databáze: MEDLINE
Externí odkaz: